By Hendra Lukman 
A groundbreaking study, leveraging an unusual vaccination policy in Wales, has provided some of the most compelling evidence to date suggesting that the shingles vaccine may offer significant protection against dementia. Researchers at Stanford Medicine analyzed extensive health records of older adults in Wales, revealing that individuals who received the shingles vaccine were approximately 20% less likely to be diagnosed with dementia in the subsequent seven years compared to their unvaccinated counterparts. This finding, published in the prestigious journal Nature, lends substantial weight to a burgeoning hypothesis: that certain viral infections known to affect the nervous system could be a contributing factor to the development of dementia. Should these results be consistently replicated in future research, they could point towards a readily available and practical intervention for dementia prevention.
Further bolstering the significance of this research, a second analysis by the same team, detailed in Cell, explored another potential benefit of the vaccine. This study indicated that the shingles vaccine might also play a therapeutic role for individuals already living with dementia, potentially slowing the progression of the condition.
The Shingles Virus: A Lifelong Companion
Shingles, also known as herpes zoster, is a viral disease characterized by a painful, blistering rash. It is caused by the reactivation of the varicella-zoster virus (VZV), the same virus responsible for chickenpox. After an initial infection, typically in childhood, VZV does not leave the body but instead lies dormant within nerve cells. In later life, particularly in older adults or individuals with compromised immune systems, this latent virus can reactivate, leading to the manifestation of shingles.
Dementia: A Growing Global Challenge and the Viral Hypothesis
Dementia is a global health crisis, currently affecting over 55 million people worldwide, with an estimated 10 million new cases diagnosed annually. For decades, the primary focus of dementia research has been on the accumulation of abnormal proteins, such as amyloid plaques and tau tangles, which are hallmarks of Alzheimer’s disease, the most prevalent form of dementia. However, despite considerable investment, these research avenues have yet to yield effective strategies for preventing or halting the disease. This lack of progress has prompted a shift in focus for some scientists, who are now investigating other potential drivers of dementia, including chronic infections by specific viruses that may inflict damage on the brain over time.
Addressing the Limitations of Previous Studies
Prior observational studies, which relied on analyzing health records, had hinted at a potential link between shingles vaccination and a reduced risk of dementia. However, these studies were hampered by a significant limitation: selection bias. Individuals who opt for vaccination are often more health-conscious in general, exhibiting behaviors such as healthier diets, increased exercise, and more regular engagement with healthcare services. These lifestyle factors are known to influence dementia risk but are often not adequately captured in medical databases, making it difficult to isolate the specific effect of the vaccine.
Dr. Pascal Geldsetzer, MD, PhD, an assistant professor of medicine and senior author of the new study, highlighted this critical issue: "All these associational studies suffer from the basic problem that people who go get vaccinated have different health behaviors than those who don’t. In general, they’re seen as not being solid enough evidence to make any recommendations on."
A "Natural Experiment" in Wales Unlocks New Insights
Approximately two years ago, Dr. Geldsetzer identified a unique opportunity arising from the way Wales had implemented its shingles vaccination program. This program’s structure functioned as what researchers term a "natural experiment," effectively circumventing much of the bias that had plagued earlier investigations. At the time of the program’s inception, Wales was utilizing a live-attenuated (weakened) form of the VZV vaccine.
The national shingles vaccination program commenced on September 1, 2013. Under this policy, any individual who had reached their 79th birthday on that date was eligible to receive the vaccine during the subsequent year. This phased approach meant that those who were 78 years old on the cut-off date would become eligible the following year, and so forth. Crucially, individuals who were 80 years or older on September 1, 2013, were deemed ineligible and would never have the opportunity to receive the vaccine under this specific program.
This age-based eligibility, tied to a precise date, created a stark division between individuals who were just below and just above the age threshold. This difference had a profound impact on vaccination access, allowing researchers to compare individuals who turned 80 shortly before September 1, 2013, with those who turned 80 shortly after. By doing so, they could observe the long-term effects of vaccine eligibility.
Dr. Geldsetzer emphasized the exceptional nature of these circumstances: "According to Geldsetzer, the detailed health records available in Wales made these circumstances about as close as possible to a randomized controlled trial without actually running one."
Comparing Near-Identical Cohorts
To capitalize on this fortuitous scenario, the research team meticulously analyzed the health records of over 280,000 older adults, aged between 71 and 88, who did not have a dementia diagnosis at the program’s start. Their analysis then zeroed in on individuals whose birthdays placed them on either side of the eligibility line, specifically comparing those who turned 80 in the week preceding September 1, 2013, with those who reached the same age in the week following.
"We know that if you take a thousand people at random born in one week and a thousand people at random, born a week later, there shouldn’t be anything different about them on average," Dr. Geldsetzer explained. "They are similar to each other apart from this tiny difference in age."
The researchers hypothesized that the propensity to seek the shingles vaccine would be roughly equivalent between these two closely matched groups. The critical distinction, however, was that only the slightly younger cohort, those not yet 80 on September 1, 2013, were permitted to receive the vaccine according to the national guidelines.
"What makes the study so powerful is that it’s essentially like a randomized trial with a control group — those a little bit too old to be eligible for the vaccine — and an intervention group — those just young enough to be eligible," Dr. Geldsetzer remarked.
Quantifying Protection Against Shingles and Dementia
The research team then embarked on a seven-year tracking of health outcomes for these comparable groups, differentiating between those who were eligible for and those who were ineligible for the vaccine. By integrating this information with actual vaccination rates, they were able to estimate the protective effect of receiving the shot. The data indicated that approximately half of the eligible individuals opted for vaccination, while virtually none of the ineligible individuals received it.
As anticipated, the vaccine demonstrated a significant reduction in shingles incidence, lowering the rate by about 37% over the seven-year follow-up period among those vaccinated. This figure aligns with established clinical trial data, acknowledging that the effectiveness of the live-attenuated vaccine may wane over time.
By 2020, when the study participants were around 86 and 87 years old, approximately one in eight individuals had developed dementia. However, for those who had received the shingles vaccine, the likelihood of receiving a dementia diagnosis was notably lower, reduced by 20% compared to the unvaccinated group.
"It was a really striking finding," Dr. Geldsetzer stated. "This huge protective signal was there, any which way you looked at the data."
Rigorous Analysis to Rule Out Alternative Explanations
The researchers undertook a comprehensive effort to identify any other potential factors that could account for the observed disparities in dementia rates. Their analysis revealed that the two groups were remarkably similar across a wide range of measurable characteristics. Educational attainment was consistent between eligible and ineligible individuals. Furthermore, those eligible for the shingles vaccine were not more likely to receive other vaccinations or preventive medical therapies, nor were they less likely to suffer from common illnesses such as diabetes, heart disease, or cancer.
The sole discernible difference between the groups was the reduced incidence of dementia diagnoses among those who had access to the shingles vaccine.
"Because of the unique way in which the vaccine was rolled out, bias in the analysis is much less likely than would usually be the case," Dr. Geldsetzer asserted.
Despite the robust initial findings, the team subjected their data to a variety of alternative analytical approaches. This included examining different age windows and focusing solely on mortality data where dementia was listed as the cause of death. Regardless of the analytical permutation, the association between vaccination and a reduced risk of dementia remained consistently evident.
"The signal in our data was so strong, so clear and so persistent," he reiterated.
Broader Benefits: From Early Decline to Advanced Dementia
The research team then broadened their inquiry to ascertain whether the apparent benefits of the vaccine were confined to dementia prevention or if they extended to individuals already exhibiting early signs of cognitive impairment. Employing the same "natural experiment" framework, they examined a wider spectrum of outcomes, ranging from mild cognitive changes to advanced stages of dementia.
Many individuals diagnosed with dementia are first identified with mild cognitive impairment (MCI), a condition characterized by deficits in memory and cognitive skills that do not yet impede independent living, as explained by Dr. Geldsetzer.
The study observed that individuals who had received the shingles vaccine were less likely to receive an MCI diagnosis during a nine-year follow-up period compared to their unvaccinated counterparts.
The researchers also investigated individuals who had been diagnosed with dementia at the commencement of the Welsh vaccination program. In this cohort, the results were particularly compelling. Individuals with dementia who received the shingles vaccine exhibited a significantly lower likelihood of dying from dementia within the subsequent nine years, as indicated on their death certificates, compared to those who did not receive the vaccine. This strongly suggests that the disease may have progressed at a slower pace in the vaccinated group.
Across the entire cohort of 7,049 Welsh seniors with dementia at the program’s outset, nearly half died from the condition during the follow-up period. However, among those with dementia who received the vaccine, approximately 30% died from dementia.
"The most exciting part is that this really suggests the shingles vaccine doesn’t have only preventive, delaying benefits for dementia, but also therapeutic potential for those who already have dementia," Dr. Geldsetzer remarked.
Sex-Specific Effects and Unanswered Questions
An intriguing pattern emerged when the researchers compared outcomes by sex. The protective effect of the shingles vaccine against dementia appeared to be substantially more pronounced in women than in men. Dr. Geldsetzer posited that this disparity might reflect underlying biological differences in immune responses or variations in how dementia manifests in men and women. On average, women tend to exhibit higher antibody responses following vaccination, and shingles itself is more prevalent in women than in men.
At present, the precise mechanisms by which the vaccine might confer protection remain unclear. Scientists are still investigating whether the benefit arises from a broad stimulation of the immune system, a reduction in the frequency of VZV reactivation, or an entirely different pathway.
Furthermore, it is yet unknown whether a newer generation of shingles vaccines, which utilize specific viral proteins and are more effective at preventing shingles, would yield similar or even enhanced effects on dementia risk.
Global Corroboration and the Call for a Randomized Trial
Dr. Geldsetzer expressed optimism that these findings will galvanize increased investment in this critical area of research. "At least investing a subset of our resources into investigating these pathways could lead to breakthroughs in terms of treatment and prevention," he stated.
Over the past two years, his team has examined health records from other countries, including England, Australia, New Zealand, and Canada, where similar shingles vaccine rollout programs were implemented. The results from these datasets have consistently mirrored the observations made in Wales. "We just keep seeing this strong protective signal for dementia in dataset after dataset," he confirmed.
The next crucial step, as envisioned by Dr. Geldsetzer, is a large-scale randomized controlled trial. Such a trial would provide the most rigorous evidence to definitively establish whether the vaccine is causally responsible for the observed reduction in dementia. In this type of study, participants would be randomly assigned to receive either the live-attenuated shingles vaccine or a placebo injection.
"It would be a very simple, pragmatic trial because we have a one-off intervention that we know is safe," he noted.
Dr. Geldsetzer is actively seeking philanthropic support to fund this pivotal research. This endeavor is particularly important given that the live-attenuated vaccine, while the subject of his strong evidence from natural experiments, is now off-patent.
He also highlighted that such a trial could yield meaningful results relatively swiftly. The Welsh data demonstrated that when dementia rates were plotted for eligible versus ineligible individuals, the two curves began to diverge after approximately 18 months.
This research was a collaborative effort, with contributions from a researcher at the Vienna University of Economics and Business. The study received funding from The Phil & Penny Knight Initiative for Brain Resilience, the Stanford Center for Digital Health, the National Institute on Aging (grant R01AG084535), the National Institute of Allergy and Infectious Diseases (grant DP2AI171011), and the Biohub, San Francisco.
